MTNB
Matinas BioPharma Holdings, Inc.
stockNYSEAMERICAN
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.55 | 2026-09-30 | +6.28% | 25.009 |
| 1M | 2.73 | 2026-09-08 | -0.73% | 0.519 |
| 3M | 9.31 | 2026-07-07 | -70.90% | 2.392 |
| 6M | 7.54 | 2026-04-07 | -64.05% | 1.155 |
| 1Y | 28.35 | 2025-10-07 | -90.44% | 0.344 |
| 2Y | 48.45 | 2024-10-07 | -94.41% | — |
| 5Y | 810.00 | 2021-10-07 | -99.67% | 0.577 |
Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) stock price today is $2.71, and today's volume is 133,174. MTNB is down 9.967% today. The 30 day average volume is 104,574. MTNB market cap is $2.65M with 979,519 shares outstanding.